Apimeds Pharmaceuticals (APUS) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing Apitox, a bee venom-based biologic for osteoarthritis (OA) and multiple sclerosis (MS).

• Holds exclusive U.S. rights to Apitox via a sublicensable, royalty-bearing license from Apimeds Korea.

• Apitox is not yet FDA-approved; prior clinical success in South Korea but U.S. approval requires further Phase III trials.

• Plans to outsource manufacturing and leverage trade secrets for process protection.

• Business strategy focuses on advancing Apitox for knee OA, exploring MS indications, and seeking strategic partnerships.

Financial performance and metrics

• No revenue generated to date; operations funded by equity and convertible notes.

• Net loss of $1.08 million for the nine months ended September 30, 2024; $777,694 net loss for 2023.

• Cash balance of $26,571 as of September 30, 2024; accumulated deficit of $4.08 million.

• Substantial doubt about ability to continue as a going concern; auditor included a going concern explanatory paragraph.

Use of proceeds and capital allocation

• Estimated net proceeds of $8.8 million (up to $10.2 million with full over-allotment) at $3.00/share IPO price.

• Proceeds to fund Phase III knee OA trial, initiate MS studies, manufacturing, repay short-term debt, and for working capital.

• Approximately $6.5 million allocated to Phase III OA trial, $1 million to MS studies, $1 million to manufacturing, and $0.3 million to debt repayment.